Two steps forward for political neutrality

Companies are ditching activism and prioritizing some of the most important issues in our culture, and Walmart Inc. is leading the way.

As shareholders make their voices heard throughout companies that represent today’s biggest brands, American Family Association (AFA) has been engaging with Walmart regarding its plans to sell mifepristone – also known as the “abortion pill.” Mifepristone is a drug commonly used to terminate pregnancy up to 70 days gestation, causing a chemically induced abortion.

In an era when companies are routinely pulled into the center of America’s most contentious debates, Walmart’s initial announcement that it was not currently selling the abortion pill was good news. But AFA wanted more. AFA wanted concrete assurance that Walmart was not planning to sell mifepristone in the future.

It is one thing for a company to say that it is not taking political sides in the moment or in response to a current controversy. It is another thing entirely for a company to say that it has no plans to do so in the future. And Walmart said just that.

The company confirmed that it has no current or future plans to sell mifepristone or seek certification to dispense it. Nor will it cover gender-transition surgeries for minors as part of its employee benefits package.

“This is a huge win for corporate neutrality and for Walmart shareholders,” said AFA President Tim Wildmon. “Businesses should focus on serving customers and stay out of the hot-button issues of our day.”

Risks and reality

While some activist groups might decry this as political, the reality is this: Not selling abortion drugs is a risk mitigation move. As controversy swirls around the drugs used in chemical abortions, more companies – including peer competitors such as Costco – are realizing that the minimal benefit is not worth the risk.

According to Bowyer Research (a firm with which AFA works closely on corporate engagement efforts), a company’s choice to sell abortive drugs is economically – not just morally – backward. The financial gain from selling mifepristone is infinitesimal compared to the legal and regulatory risk that choice creates.

Transparency and trust

Walmart understands political neutrality. Its 2024 rollback of DEI policies was a major step toward restoring shareholder trust. Not taking sides in the abortion debate is now another step.

Walmart also publicly disclosed its employee health care coverage, which explicitly excludes gender-transition “care” for children. Its benefits book contains the following clause on p. 123: “Gender reassignment surgery is not considered medically necessary for individuals under the age of 18.”

This is a bold declaration of neutrality, especially in a culture where corporations are pressured to take a woke stance.

However, companies that do cover gender-transition surgeries for minors may risk brand and reputation damage as well as growing legal challenges.

In January 2026, a New York jury awarded $2 million in damages in the first detransitioner medical malpractice case to reach a verdict. The detransitioner was only 16 when she had surgery. (See p. 6.)

In February 2026, both the American Medical Association and the American Society of Plastic Surgeons recommended that irreversible surgical interventions generally be deferred until adulthood, citing insufficient long-term evidence and emerging legal and ethical concerns.

This is a risk reassessment that corporations simply cannot ignore.

Walmart did what no other company AFA has engaged with has done: Walmart took a major step forward for corporate transparency and investor trust by publicly disclosing what its health plan does and does not cover.

Corporate engagement, such as AFA’s efforts, works because it encourages companies to focus on their primary mission – serving customers and shareholders, and it keeps them on the path to continued success.